MIRM

Mirum Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

51.830

-0.34(-0.652%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

52.330

Open

52.010

VWAP

51.70

Vol

247.80K

Mkt Cap

2.57B

Low

51.220

Amount

12.81M

EV/EBITDA(TTM)

Total Shares

47.13M

2.66B

EV/OCF(TTM)

P/S(TTM)

6.72

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

117.22M

+17.91%

112.71M

+24.71%

107.83M

+38.47%

Estimates Revision

The market is revising Upward the revenue expectations for Mirum Pharmaceuticals, Inc. (MIRM) for FY2025, with the revenue forecasts being adjusted by 4.52% over the past three months. During the same period, the stock price has changed by 27.03%.

Revenue Estimates for FY2025

Revise Upward

+4.52%

In Past 3 Month

Stock Price

Go Up

+27.03%

In Past 3 Month

7 Analyst Rating

37.82% Upside

Wall Street analysts forecast MIRM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIRM is 71.43 USD with a low forecast of 56.00 USD and a high forecast of 77.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

0 Sell

Strong Buy

37.82% Upside

Current: 51.830

Low

56.00

Averages

71.43

High

77.00

37.82% Upside

Current: 51.830

Low

56.00

Averages

71.43

High

77.00

Evercore ISI

Outperform

maintain

$68 -> $76

2025-07-11

Reason

Evercore ISI

Price Target

$68 -> $76

2025-07-11

maintain

Outperform

Reason

Evercore ISI raised the firm's price target on Mirum Pharmaceuticals to $76 from $68 and keeps an Outperform rating on the shares. The firm adjusted price targets in Smid-cap biotechnology as part of a research note discussing 2026 stock ideas. There is a "notable lengthening" of time horizons among investors, which is a positive sign for the broader small cap biotech markets, the analyst tells investors in a research note.

H.C. Wainwright

NULL -> Buy

initiated

$73

2025-05-19

Reason

H.C. Wainwright

Price Target

$73

2025-05-19

initiated

NULL -> Buy

Reason

Raymond James

Ryan Deschner

Strong Buy

maintain

$73 -> $77

2025-05-13

Reason

Raymond James

Ryan Deschner

Price Target

$73 -> $77

2025-05-13

maintain

Strong Buy

Reason

Raymond James analyst Ryan Deschner raised the firm's price target on Mirum Pharmaceuticals to $77 from $73 and keeps a Strong Buy rating on the shares. The price target increase is driven by bile acid portfolio and Livmarli net sales in addition to raised guidance for fiscal 2025, the analyst tells investors in a research note.

Citi

Buy

maintain

$72

2025-05-12

Reason

Citi

Price Target

$72

2025-05-12

maintain

Buy

Reason

Citizens JMP

Jonathan Wolleben

Outperform

maintain

$74 -> $76

2025-05-09

Reason

Citizens JMP

Jonathan Wolleben

Price Target

$74 -> $76

2025-05-09

maintain

Outperform

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Maintains

$66 → $72

2025-02-28

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$66 → $72

2025-02-28

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Mirum Pharmaceuticals Inc (MIRM.O) is -46.56, compared to its 5-year average forward P/E of -17.15. For a more detailed relative valuation and DCF analysis to assess Mirum Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-17.15

Current PE

-46.56

Overvalued PE

-0.52

Undervalued PE

-33.77

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-19.75

Current EV/EBITDA

-120.41

Overvalued EV/EBITDA

6.02

Undervalued EV/EBITDA

-45.52

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

7.28

Current PS

5.63

Overvalued PS

12.52

Undervalued PS

2.05

Financials

Annual

Quarterly

FY2025Q1

YoY :

+61.20%

111.59M

Total Revenue

FY2025Q1

YoY :

-42.64%

-15.18M

Operating Profit

FY2025Q1

YoY :

-41.94%

-14.68M

Net Income after Tax

FY2025Q1

YoY :

-44.44%

-0.30

EPS - Diluted

FY2025Q1

YoY :

-113.17%

-2.00M

Free Cash Flow

FY2025Q1

YoY :

+6.91%

79.37

Gross Profit Margin - %

FY2025Q1

YoY :

-60.84%

-7.35

FCF Margin - %

FY2025Q1

YoY :

-63.99%

-13.15

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

205.7K

USD

3-6

Months

5.5M

USD

6-9

Months

1.4M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

280.1K

USD

Months

6-9

0.0

USD

Months

0-12

24.1K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

409.2K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

224.7K

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

205.7K

USD

3-6

Months

5.5M

USD

6-9

Months

1.4M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

280.1K

USD

Months

6-9

0.0

USD

Months

0-12

24.1K

USD

Months

MIRM News & Events

Events Timeline

2025-05-19 (ET)

2025-05-19

09:07:47

Mirum Pharmaceuticals appoints Doug Sheehy as Chief Legal Officer

2025-05-07 (ET)

2025-05-07

16:22:33

Mirum Pharmaceuticals reports Q1 EPS (30c), consensus (27c)

2025-04-14 (ET)

2025-04-14

09:20:05

Mirum Pharmaceuticals receives FDA approval for Livmarli tablet formulation

News

2.0

07-15NASDAQ.COM

Mirum Hits All-Time High - Is There More Upside Ahead?

5.0

07-10Yahoo Finance

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

8.0

06-23NASDAQ.COM

Interesting MIRM Put And Call Options For August 15th

People Also Watch

IVT

Inventrust Properties Corp

Lightspeed Commerce Inc

Harmony Biosciences Holdings Inc

Huron Consulting Group Inc

LeMaitre Vascular Inc

Retail Opportunity Investments Corp

Vishay Intertechnology Inc

FAQ

What is Mirum Pharmaceuticals Inc (MIRM) stock price today?

The current price of MIRM is 51.83 USD — it has decreased -0.65 % in the last trading day.

MIRM

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

MIRM News & Events

Events Timeline

News

People Also Watch

FAQ

What is Mirum Pharmaceuticals Inc (MIRM) stock price today?

What is Mirum Pharmaceuticals Inc (MIRM)'s business?

What is the price predicton of MIRM Stock?

What is Mirum Pharmaceuticals Inc (MIRM)'s revenue for the last quarter?

What is Mirum Pharmaceuticals Inc (MIRM)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Mirum Pharmaceuticals Inc (MIRM)'s fundamentals?

How many employees does Mirum Pharmaceuticals Inc (MIRM). have?

What is Mirum Pharmaceuticals Inc (MIRM) market cap?